Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma

Clinical trial NCT00116363 · UNKNOWN

Trial details

NCT number: NCT00116363
Sponsor: Introgen Therapeutics
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma Neoplasm Metastasis

Start date: 2005-03-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.